(NASDAQ: MRKR) Marker Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.33%.
Marker Therapeutics's earnings in 2026 is -$12,163,620.On average, 5 Wall Street analysts forecast MRKR's earnings for 2026 to be -$16,893,212, with the lowest MRKR earnings forecast at -$24,999,687, and the highest MRKR earnings forecast at -$10,679,138. On average, 5 Wall Street analysts forecast MRKR's earnings for 2027 to be -$17,290,033, with the lowest MRKR earnings forecast at -$24,672,893, and the highest MRKR earnings forecast at -$3,326,289.
In 2028, MRKR is forecast to generate $8,276,540 in earnings, with the lowest earnings forecast at -$16,829,854 and the highest earnings forecast at $25,209,768.